233 related articles for article (PubMed ID: 20185740)
1. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet.
Chan DC; Watts GF; Gan SK; Ooi EM; Barrett PH
Diabetes Care; 2010 May; 33(5):1134-9. PubMed ID: 20185740
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein-apolipoprotein B-100 in obesity.
Chan DC; Watts GF; Gan S; Wong AT; Ooi EM; Barrett PH
Arterioscler Thromb Vasc Biol; 2010 May; 30(5):1043-50. PubMed ID: 20150556
[TBL] [Abstract][Full Text] [Related]
3. Association between skeletal muscle fat content and very-low-density lipoprotein-apolipoprotein B-100 transport in obesity: effect of weight loss.
Chan DC; Gan SK; Wong AT; Barrett PH; Watts GF
Diabetes Obes Metab; 2014 Oct; 16(10):994-1000. PubMed ID: 24821431
[TBL] [Abstract][Full Text] [Related]
4. Effect of ω-3 fatty acid ethyl esters on apolipoprotein B-48 kinetics in obese subjects on a weight-loss diet: a new tracer kinetic study in the postprandial state.
Wong AT; Chan DC; Barrett PH; Adams LA; Watts GF
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1427-35. PubMed ID: 24606094
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.
Chan DC; Watts GF; Redgrave TG; Mori TA; Barrett PH
Metabolism; 2002 Aug; 51(8):1041-6. PubMed ID: 12145779
[TBL] [Abstract][Full Text] [Related]
6. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease.
Fabbrini E; Mohammed BS; Korenblat KM; Magkos F; McCrea J; Patterson BW; Klein S
J Clin Endocrinol Metab; 2010 Jun; 95(6):2727-35. PubMed ID: 20371660
[TBL] [Abstract][Full Text] [Related]
7. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome.
Chan DC; Watts GF; Ng TW; Yamashita S; Barrett PH
Eur J Clin Invest; 2008 Oct; 38(10):743-51. PubMed ID: 18837799
[TBL] [Abstract][Full Text] [Related]
8. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men.
Riches FM; Watts GF; Hua J; Stewart GR; Naoumova RP; Barrett PH
J Clin Endocrinol Metab; 1999 Aug; 84(8):2854-61. PubMed ID: 10443691
[TBL] [Abstract][Full Text] [Related]
9. Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels.
Ng TW; Watts GF; Barrett PH; Rye KA; Chan DC
Diabetes Care; 2007 Nov; 30(11):2945-50. PubMed ID: 17686833
[TBL] [Abstract][Full Text] [Related]
10. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity.
Riches FM; Watts GF; Naoumova RP; Kelly JM; Croft KD; Thompson GR
Int J Obes Relat Metab Disord; 1998 May; 22(5):414-23. PubMed ID: 9622338
[TBL] [Abstract][Full Text] [Related]
11. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia.
Tremblay AJ; Lamarche B; Cohn JS; Hogue JC; Couture P
Arterioscler Thromb Vasc Biol; 2006 May; 26(5):1101-6. PubMed ID: 16528005
[TBL] [Abstract][Full Text] [Related]
12. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin.
Telford DE; Sutherland BG; Edwards JY; Andrews JD; Barrett PH; Huff MW
J Lipid Res; 2007 Mar; 48(3):699-708. PubMed ID: 17130282
[TBL] [Abstract][Full Text] [Related]
13. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease.
Fabbrini E; Mohammed BS; Magkos F; Korenblat KM; Patterson BW; Klein S
Gastroenterology; 2008 Feb; 134(2):424-31. PubMed ID: 18242210
[TBL] [Abstract][Full Text] [Related]
14. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia.
Tremblay AJ; Lamarche B; Hogue JC; Couture P
J Lipid Res; 2009 Jul; 50(7):1463-71. PubMed ID: 19305020
[TBL] [Abstract][Full Text] [Related]
15. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet.
Muraoka T; Aoki K; Iwasaki T; Shinoda K; Nakamura A; Aburatani H; Mori S; Tokuyama K; Kubota N; Kadowaki T; Terauchi Y
Metabolism; 2011 May; 60(5):617-28. PubMed ID: 20673929
[TBL] [Abstract][Full Text] [Related]
16. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease.
Sullivan S; Kirk EP; Mittendorfer B; Patterson BW; Klein S
Hepatology; 2012 Jun; 55(6):1738-45. PubMed ID: 22213436
[TBL] [Abstract][Full Text] [Related]
18. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
[TBL] [Abstract][Full Text] [Related]
19. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.
van Heek M; Austin TM; Farley C; Cook JA; Tetzloff GG; Davis HR
Diabetes; 2001 Jun; 50(6):1330-5. PubMed ID: 11375333
[TBL] [Abstract][Full Text] [Related]
20. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice.
Sugizaki T; Watanabe M; Horai Y; Kaneko-Iwasaki N; Arita E; Miyazaki T; Morimoto K; Honda A; Irie J; Itoh H
Endocrinology; 2014 Aug; 155(8):2810-9. PubMed ID: 24773344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
